Category - Developments

Developments

IntelGenx, atai Life Sciences in strategic pact; atai to purchase significant ownership stake

IntelGenx (TSXV:IGX; OTCQB:IGXT), a leader in pharmaceutical films, agreed to a strategic partnership with atai Life Sciences to develop treatments for mental health disorders. Under the accord, atai initially will...

March 15, 2021

Developments

Coridea, Deerfield to accelerate medtech innovation at NYC site

Coridea and Deerfield Management have established Deerfield Device Design and Development Catalyst to advance medtech innovation and accelerate the formation of commercial companies. Coridea is a medtech incubator;...

March 9, 2021

Developments

Azura Ophthalmics posts positive Phase 2 results in Meibomian gland dysfunction

Closely-held Azura Ophthalmics of Israel announced positive topline results from a Phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). The company’s...

March 5, 2021

Developments

BriaCell Therapeutics closes $25-million public offering

BriaCell Therapeutics (TSXV:BCT; NASDAQ:BCTX, BCTXW) closed a U.S. offering of 4,852,353 units at a price of $4.25 a unit and 1,030,000 pre-funded units at a price of $4.24 a unit for gross proceeds of about $25-million...

February 26, 2021

Developments

KA Imaging to present lateral dual-energy X-ray views at ECR 2021

Closely-held KA Imaging will present a poster on results from a study examining the feasibility of lateral chest dual-energy subtraction radiography using a stacked single-exposure multi-layer x-ray detector at the...

February 24, 2021

Developments

IntelGenx receives U.S. patent allowance for DisinteQ disintegrating THC oral film

The U.S. Patent and Trademark Office granted a notice of allowance for an IntelGenx (TSXV:IGX; OTCQB:IGXT) patent application entitled, “Film Dosage Form with Extended Release Mucoadhesive Particles.” This film...

February 17, 2021

Developments

HEXO to acquire Zenabis Global

HEXO (TSX, NYSE:HEXO) agreed to acquire Zenabis Global (TSX:ZENA) by way of a court-approved plan of arrangement under the Business Corporations Act of British Columbia, in an all-share transaction valued at...

February 16, 2021

Developments

Notch Therapeutics in $85-million financing for stem cell cancer immunotherapies

Closely-held Notch Therapeutics closed an $85-million series A financing to support continuing development of its portfolio of induced pluripotent stem cell (iPSC)-derived T-cell therapeutic product candidates and...

February 10, 2021

Developments

MD Anderson completes second cohort dosing in Phase 1b trial of Soricimed’s SOR-C13

MD Anderson Cancer Center has completed patient dosing in the second cohort of a Phase 1b investigator-initiated trial of Soricimed Biopharma’s lead drug candidate, SOR-C13, for the targeted treatment of solid tumor...

February 8, 2021

Developments

IntelGenx files provisional U.S. patent for VetaFilm high loading oral film platform

IntelGenx (TSXV:IGX; OTCQB:IGXT) filed a new provisional patent application with the U.S. Patent and Trademark Office entitled, “High Loading Oral Film Formulation.” The patent application covers the incorporation of...

February 8, 2021

Category - Developments

Subscribe